Deletions and/or mutations of TP53 are associated with poor prognosis in patients with chronic lymphocytic leukaemia (CLL), even when these abnormalities are not present in the predominant clonal population (Rossi et al, 2014). Dysfunction of the TP53-CDKN1A (p21) pathway correlates strongly with TP53 structural abnormalities (Carter et al, 2004; Best et al, 2008), however 9·5% of unselected CLL cases have been reported to have an impaired CDKN1A response to DNA damage despite normal TP53 upregulation, termed Type C dysfunction (Johnson et al, 2009)...
- Alleles Cyclin-Dependent Kinase Inhibitor p21/*genetics/*metabolism *DNA Damage Gene Expression Genotype Humans Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy/*genetics/*metabolism *Polymorphism, Genetic Polymorphism, Single Nucleotide *Signal Transduction Tumor Suppressor Protein p53/*genetics/*metabolism * tp53 *cell signalling *chronic lymphocytic leukaemia
- chronic lymphocytic leukaemia
- cell signalling